This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Viral Infections  • World Health  • Pulmonary Diseases, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2004;292:916.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scientists have developed an experimental nasal spray vaccine that may protect individuals from severe acute respiratory syndrome (SARS) virus infection if another outbreak should occur (Lancet. 2004;363:2122-2127). Researchers from the National Institute of Allergy and Infectious Diseases, in Bethesda, Md, designed the vaccine by creating a recombinant attenuated parainfluenza virus that expresses the SARS envelope spike protein. (This strain of virus is being developed as a live attenuated intranasal pediatric vaccine against human parainfluenza virus type 3.) The spike protein is a viral surface protein used by the SARS virus to invade human cells.

A new nasal spray vaccine against the SARS virus is effective in monkeys and is ready for clinical trials in humans. (Photo credit: Fred Murphy/CDC)

In the study, 8 African green monkeys were immunized, 4 with a single dose of the vaccine and 4 with a control vaccine. Following a SARS . . . [Full Text of this Article]